Arcus Biosciences
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 577
- Market Cap
- -
- Website
- http://www.arcusbio.com
- Introduction
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer
- First Posted Date
- 2019-02-19
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 77
- Registration Number
- NCT03846310
- Locations
- π°π·
Chungbuk National University Hospital, Cheongju-si, Korea, Republic of
π°π·Bundang CHA Medical Center, Seongnam-si, Korea, Republic of
π°π·Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies
- Conditions
- Interventions
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT03720678
- Locations
- πΊπΈ
Carolina BioOncology Institute, Huntersville, North Carolina, United States
πΊπΈArizona Clinical Research Center, Tucson, Arizona, United States
π¦πΊPeninsula & South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia
A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT03719326
- Locations
- π¦πΊ
Peninsula & South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia
πΊπΈVirginia Cancer Specialists, PC, Fairfax, Virginia, United States
πΊπΈTexas Oncology, P.A. - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
A Study to Investigate the Safety of AB680 in Healthy Volunteers
- First Posted Date
- 2018-09-19
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT03677973
- Locations
- π¦πΊ
Melbourne, VIC, Melbourne, Victoria, Australia
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT03629756
- Locations
- πΊπΈ
The Angeles Clinic and Research Institute, Los Angeles, California, United States
π¦πΊCabrini Health Limited, Malvern, Australia
πΊπΈScottsdale Healthcare Hospitals dba HonorHealth, Scottsdale, Arizona, United States
A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT03628677
- Locations
- πΊπΈ
MD Anderson Cancer Center, Houston, Texas, United States
π¦πΊTweed Hospital, Tweed Heads, New South Wales, Australia
πΊπΈThe Angeles Clinic and Research Institute, Los Angeles, California, United States